Skip to main content
PMC home page
British Journal of Cancer logoLink to British Journal of Cancer
. 1995 Oct;72(4):958–963. doi: 10.1038/bjc.1995.441

The prognostic value of morphometry in advanced epithelial ovarian cancers.

M Katsoulis 1, J Lekka 1, I Vlachonikolis 1, G S Delides 1
PMCID: PMC2034059  PMID: 7547248

Abstract

The relationship between morphometric and clinical data was assessed in a series of 60 advanced ovarian carcinomas. Morphometric parameters included nuclear area, nuclear perimeter, shortest and longest nuclear axis, roundness coefficient, volume percentage of epithelium (VPE) and mitotic index. All patients had at least 5 years of follow-up. Univariate survival analysis showed that FIGO stage (P < 0.001), VPE (P < 0.001), mean nuclear area (P < 0.001) and size of residual tumour (P < 0.001) are significantly associated with survival. When the response rate of these patients to cisplatin combination chemotherapy was evaluated, variables with good prognostic outcome were residual tumour size (P = 0.01), mean nuclear area (P = 0.0006) and s.d. of nuclear area (P = 0.0019). We conclude that morphometric parameters are able to support diagnostic and therapeutic decisions.

Full text

PDF
958

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Baak J. P., Blanco A. A., Kurver P. H., Langley F. A., Boon M. E., Lindeman J., Overdiep S. H., Nieuwlaat A., Brekelmans E. Quantitation of borderline and malignant mucinous ovarian tumours. Histopathology. 1981 Jul;5(4):353–360. doi: 10.1111/j.1365-2559.1981.tb01797.x. [DOI] [PubMed] [Google Scholar]
  2. Baak J. P., Chan K. K., Stolk J. G., Kenemans P. Prognostic factors in borderline and invasive ovarian tumors of the common epithelial type. Pathol Res Pract. 1987 Dec;182(6):755–774. doi: 10.1016/s0344-0338(87)80040-7. [DOI] [PubMed] [Google Scholar]
  3. Baak J. P., Fox H., Langley F. A., Buckley C. H. The prognostic value of morphometry in ovarian epithelial tumors of borderline malignancy. Int J Gynecol Pathol. 1985;4(3):186–191. doi: 10.1097/00004347-198509000-00003. [DOI] [PubMed] [Google Scholar]
  4. Baak J. P., Langley F. A., Talerman A., Delemarre J. F. Interpathologist and intrapathologist disagreement in ovarian tumor grading and typing. Anal Quant Cytol Histol. 1986 Dec;8(4):354–357. [PubMed] [Google Scholar]
  5. Baak J. P., Schipper N. W., Wisse-Brekelmans E. C., Ceelen T., Bosman F. T., van Geuns H., Wils J. The prognostic value of morphometrical features and cellular DNA content in cis-platin treated late ovarian cancer patients. Br J Cancer. 1988 May;57(5):503–508. doi: 10.1038/bjc.1988.114. [DOI] [PMC free article] [PubMed] [Google Scholar]
  6. Baak J. P., Wisse-Brekelmans E. C., Langley F. A., Talerman A., Delemarre J. F. Morphometric data to FIGO stage and histological type and grade for prognosis of ovarian tumours. J Clin Pathol. 1986 Dec;39(12):1340–1346. doi: 10.1136/jcp.39.12.1340. [DOI] [PMC free article] [PubMed] [Google Scholar]
  7. Edmonson J. H., McCormack G. W., Fleming T. R., Cullinan S. A., Krook J. E., Malkasian G. D., Podratz K. C., Mailliard J. A., Jefferies J. A., Barlow J. F. Comparison of cyclophosphamide plus cisplatin versus hexamethylmelamine, cyclophosphamide, doxorubicin, and cisplatin in combination as initial chemotherapy for stage III and IV ovarian carcinomas. Cancer Treat Rep. 1985 Nov;69(11):1243–1248. [PubMed] [Google Scholar]
  8. Friedlander M. L., Dembo A. J. Prognostic factors in ovarian cancer. Semin Oncol. 1991 Jun;18(3):205–212. [PubMed] [Google Scholar]
  9. Haapasalo H., Atkin N. B., Collan Y., Pesonen E., Paljärvi L. Tumour ploidy, morphometry, histological grading and clinical features in ovarian carcinoma: mutual relations. Anal Cell Pathol. 1991 Sep;3(5):261–271. [PubMed] [Google Scholar]
  10. Haapasalo H., Collan Y., Atkin N. B., Pesonen E., Seppä A. Prognosis of ovarian carcinomas: prediction by histoquantitative methods. Histopathology. 1989 Aug;15(2):167–178. doi: 10.1111/j.1365-2559.1989.tb03064.x. [DOI] [PubMed] [Google Scholar]
  11. Neijt J. P., ten Bokkel Huinink W. W., van der Burg M. E., van Oosterom A. T., Willemse P. H., Heintz A. P., van Lent M., Trimbos J. B., Bouma J., Vermorken J. B. Randomized trial comparing two combination chemotherapy regimens (CHAP-5 v CP) in advanced ovarian carcinoma. J Clin Oncol. 1987 Aug;5(8):1157–1168. doi: 10.1200/JCO.1987.5.8.1157. [DOI] [PubMed] [Google Scholar]
  12. Omura G. A., Bundy B. N., Berek J. S., Curry S., Delgado G., Mortel R. Randomized trial of cyclophosphamide plus cisplatin with or without doxorubicin in ovarian carcinoma: a Gynecologic Oncology Group Study. J Clin Oncol. 1989 Apr;7(4):457–465. doi: 10.1200/JCO.1989.7.4.457. [DOI] [PubMed] [Google Scholar]
  13. Perez R. P., Hamilton T. C., Ozols R. F., Young R. C. Mechanisms and modulation of resistance to chemotherapy in ovarian cancer. Cancer. 1993 Feb 15;71(4 Suppl):1571–1580. doi: 10.1002/cncr.2820710424. [DOI] [PubMed] [Google Scholar]

Articles from British Journal of Cancer are provided here courtesy of Cancer Research UK

RESOURCES